利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1335 条记录 (耗时 0.053 秒)

    C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE
    1.
    发明公开
    C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE 审中-公开
    C2-CARBOCYCLISCHE IMINOTHIAZINDIOXIDE ALS BACE-INHIBITOREN，ZUSAMMENSETZUNGEN UND DEREN VERWENDUNG

    公开(公告)号：EP3148996A1

    公开(公告)日：2017-04-05

    申请号：EP15803641.8

    申请日：2015-05-28

    申请人： Merck Sharp & Dohme Corp.

    发明人： WALSH, Shawn P. ,  CUMMING, Jared N. ,  HE, Shuwen ,  TAOKA, Brandon M. ,  TRUONG, Quang T. ,  WU, Wen-Lian

    IPC分类号： C07D417/14

    CPC分类号： C07D487/04 ,  C07D471/04

    摘要： In its many embodiments, the present invention provides certain C2-carbocyclic iminothiazine dioxide compounds, including compounds Formula (I); or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, ring A, RA, m, ring B, RB, n, ring C, RC and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

    摘要翻译： 在其许多实施方案中，本发明提供某些C2-碳环亚氨基噻嗪二氧化物化合物，包括式（I）化合物; 或其互变异构体和所述化合物和所述互变异构体的药学上可接受的盐，其中R1，R2，环A，RA，m，环B，RB，n，环C，RC和p如本文所定义。 本发明的新化合物可用作BACE抑制剂和/或用于治疗和预防与其相关的各种病症。 还公开了包含一种或多种这样的化合物（单独和与一种或多种其它活性剂组合）的药物组合物及其制备和使用方法，包括用于治疗阿尔茨海默氏病的药物组合物。

    PHARMACEUTICAL SALTS OF AN OREXIN RECEPTOR ANTAGONIST
    5.
    发明公开
    PHARMACEUTICAL SALTS OF AN OREXIN RECEPTOR ANTAGONIST 审中-公开
    药剂师SALZE EINES OREXINREZEPTORANTAGONISTEN

    公开(公告)号：EP3134092A1

    公开(公告)日：2017-03-01

    申请号：EP15782608.2

    申请日：2015-04-16

    申请人： Merck Sharp & Dohme Corp.

    发明人： MCNEVIN, Michael ,  LOHANI, Sachin

    IPC分类号： A61K31/551 ,  A61K31/423 ,  C07D413/14

    摘要： The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.

    摘要翻译： 本发明涉及作为食欲素受体的拮抗剂的苏维素的药学上可接受的盐。 suvorexant的药学上可接受的盐可用于治疗或预防涉及食欲肽受体的神经和精神疾病和疾病。 本发明进一步涉及包含药学上可接受的盐酸盐的盐的药物组合物。